Salma Health

What Salma Health does

Salma Health, Inc. is a Delaware-incorporated, California-headquartered integrated brain health company that operates specialized clinics combining advanced diagnostics, rapid-acting neuromodulation therapies, and AI-enabled care coordination. The company treats depression, anxiety, PTSD, OCD, traumatic brain injury, headache and facial pain, memory and dementia conditions, and ADHD across four California sites (La Jolla, Laguna Hills, Fremont, with Berkeley/Los Angeles expansion planned), using modalities including the FDA-cleared SAINT neuromodulation protocol, transcranial magnetic stimulation (TMS), Spravato (esketamine) therapy, anti-amyloid infusions, botulinum toxin for chronic migraine, neuropsychological assessment, and psychiatric medication management. Advanced diagnostics span MRI, fMRI, EEG/QEEG, cognitive testing, laboratory panels, and genetic testing.

The company monetizes primarily through fee-for-service clinical care billed to most major U.S. insurance carriers (Aetna, Blue Shield of California, Anthem, Cigna, Optum, TRICARE, Medicare, Medi-Cal) and self-pay patients, supplemented by clinical trial contracts with pharmaceutical and medical device companies conducted in a HIPAA-compliant research sandbox. Salma Health unified these services through "Brain Health OS," a proprietary AI-driven platform that applies generative AI, recommendation engines, and process automation to clinical decision support, predictive models of care, and cross-clinic coordination, while a parallel Brain Health Data Platform aggregates neural, physiological, and digital patient markers for real-world evidence generation.

Salma Health launched from stealth in February 2026 with an $80 million Series A co-led by Mubadala Capital and ARCH Venture Partners, with participation from Lingotto Horizon and Averin Capital. The company is led by CEO Alaa Halawa (who concurrently serves as Head of Healthcare at Mubadala Capital) and CMO Brandon Bentzley (co-developer of the SAINT protocol), with a founding team that includes Ayman AlAbdallah, Emily Philips-Bru, and Zeena Ojjeh. Patient acquisition runs through direct clinic channels, a self-serve online portal, telehealth/IOP, provider referrals (including a dedicated Bay Area Ocean Psychiatry pathway), and earned media.

Name

Salma Health

Legal name

Salma Health, Inc.

Website

https://salmahealth.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

51–100 employees

Short description

Salma Health operates integrated brain health clinics in California combining advanced diagnostics, neuromodulation therapies (SAINT, TMS, esketamine), and AI-driven care coordination for patients with depression, PTSD, TBI, and neurodegenerative conditions. Launched in 2026 with $80M Series A.

Ownership category

akta.pro rank

Product category

Behavioral Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Medicaid Vision Benefits (Managed Care) (HLAEAJAE)

akta.pro secondary industry

Integrated Physical-Behavioral-Social Care (Whole-Person) Medicaid Plans (HLAEAEAI)

Keywords

• Integrated brain health
• Neuromodulation therapy
• Treatment-resistant depression
• Advanced brain diagnostics
• Interventional psychiatry

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Healthcare Services: Fee-for-service healthcare delivery model providing diagnostic assessments, therapeutic treatments (TMS, SAINT, esketamine), psychiatric care, and intensive outpatient programs. Services are billed to insurance or self-pay patients with Good Faith Estimates available under the No Surprises Act.
2. Clinical Trials Services: Conducting clinical trials in partnership with pharmaceutical and medical device companies to expand therapeutic options for patients, generating revenue through research contracts and partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Salma Health delivers personalized brain and behavioral health care through physical clinics and telehealth, integrating advanced diagnostics (MRI, fMRI, EEG, cognitive and genetic testing) with rapid-acting neuromodulation treatments including SAINT, TMS, and esketamine therapy, plus psychiatric care, medication management, and intensive outpatient programs. Its proprietary Brain Health OS platform uses generative AI to coordinate care, match patients to treatments, and aggregate deep brain health datasets. Services are billed to major insurance plans (Aetna, Blue Shield of California, Anthem, Cigna, Optum, TRICARE, Medicare, Medi-Cal) with self-pay options.

Product overview

Salma Health operates as an integrated brain health platform combining specialized in-person clinics with telehealth solutions, clinical research capabilities, and proprietary AI-driven technology. The core offering centers on advanced neuromodulation treatments (TMS, SAINT, esketamine), comprehensive diagnostics (MRI, EEG, cognitive testing), and intensive outpatient therapy. The ecosystem is unified by Brain Health OS—a generative AI platform powering clinical decision support and care coordination—alongside a Brain Health Data Platform aggregating neural, physiological, and digital patient markers for predictive analytics. Salma Health's model integrates psychiatrists, neurologists, psychologists, and crisis care services treating depression, OCD, PTSD, anxiety, traumatic brain injury, migraines, memory disorders, and neurodegenerative conditions across clinic locations in California.

Differentiator

Problem solved

Functional benefit

Products and services

• Transcranial Magnetic Stimulation (TMS) Therapy

Quantifiable outcome

• 79% remission rate in double-blinded randomized controlled trial for SAINT treatment vs. 13% placebo
• +1 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Pharmaceutical CompaniescoreStrategic or Co-development Partner · 26 February 2026Building innovation platform to partner with pharmaceutical companies and medical device manufacturers, providing patients access to experimental therapeutics through FDA-regulated clinical trials. HIPAA-compliant research sandbox enables companies to innovate alongside Salma Health's research initiatives.
• Medical Device ManufacturerscoreStrategic or Co-development Partner · 26 February 2026Strategic partnerships with medical device companies to expand access to advanced therapeutic devices and contribute to real-world evidence generation for FDA pathways.
• Academic InstitutionsminorStrategic or Co-development PartnerStrategic partnerships with academic institutions to establish new diagnostic protocols, advance FDA pathways for personalized interventions, and create real-world evidence frameworks.
• Healthcare SystemsminorStrategic or Co-development PartnerStrategic partnerships with healthcare systems to expand access to integrated brain health care and establish new clinical guidelines.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Pasadena Neuropsychiatry: California-based outpatient psychiatry and neuropsychology practice offering integrated psychiatric and neurological assessment. Comparable regional specialty mental health operator overlapping with Salma's California footprint and integrated diagnostic positioning.
• Two Chairs: Tech-forward outpatient therapy practice using measurement-based care and matching algorithms. Comparable as an integrated, data-driven outpatient mental health operator, though Two Chairs is therapy-led rather than neuromodulation-led.

Direct peers

• Talkiatry: Tech-enabled psychiatry practice delivering outpatient psychiatric care in-person and via telehealth with broad insurance acceptance. Comparable as a multi-state, insurance-credentialed outpatient mental health operator, though Talkiatry is more tele-first and less neuromodulation-heavy.
• Greenbrook TMS: Operates a national network of outpatient clinics delivering TMS therapy for depression and other mental health conditions. Closest publicly-traded analog to Salma's clinic-led TMS/SAINT model, though Greenbrook is TMS-only and lacks Salma's integrated neurology/diagnostics stack.
• Magnus Medical: Co-founded by Salma's CMO Dr. Brandon Bentzley, Magnus Medical commercializes the SAINT neuromodulation protocol. Closest direct comparable — Salma is essentially a clinical-delivery vehicle that also uses a technology Magnus originated, making them simultaneous partners and potential competitors.
• Lyra Health: Mental health benefits platform combining in-person and virtual therapy, coaching, and psychiatry for employer-sponsored populations. Comparable as a tech-enabled, integrated mental health care delivery model aiming to consolidate fragmented services under one platform.
• Apollo Behavioral Health: Regional outpatient mental health and TMS clinic operator. Comparable as a specialty brain-health clinic network offering TMS and integrative psychiatric care, though at smaller scale and without SAINT.

Broad incumbents

• Cerebral: National telehealth mental health company prescribing medication management and therapy. Comparable as a tech-enabled mental health delivery business serving insured populations, though Cerebral is tele-only and has faced regulatory scrutiny on prescribing practices.
• Spring Health: Larger, well-capitalized mental health benefits and care navigation platform. Comparable in mission to consolidate fragmented mental health care via technology, but operates as a broad employer benefits layer rather than a specialty clinic operator.

Others

• Neuronetics: Manufacturer of NeuroStar TMS systems sold to clinics including Salma. Adjacent ecosystem participant — a device supplier enabling Salma's conventional TMS offering rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/salmahealthclinics
• LinkedInlinkedin.com/company/salmahealth
• Instagraminstagram.com/salmahealthclinics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salma Health